Page 416 - Williams Hematology ( PDFDrive )

390 Part V: Therapeutic Principles Chapter 24: Treatment of Infections in the Immunocompromised Host 391

62. Walsh TJ, Anaissie EJ, Denning DW, et al: Treatment of aspergillosis: Clinical practice 92. Jassal M, Bishai WR: Extensively drug-resistant tuberculosis. Lancet Infect Dis 9:19,
guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46:327, 2008. 2009.
63. Williams K, Mansh M, Chin-Hong P, et al: Voriconazole-associated cutaneous malig- 93. Hodgson-Viden H, Grundy PE, Robinson JL: Early discontinuation of intravenous
nancy: A literature review on photocarcinogenesis in organ transplant recipients. Clin antimicrobial therapy in pediatric oncology patients with febrile neutropenia. BMC
Infect Dis 58:997, 2014. Pediatr 5:10, 2005.
64. Pascual A, Calandra T, Bolay S, et al: Voriconazole therapeutic drug monitoring in 94. Barton TD, Schuster MG: The cause of fever following resolution of neutropenia in
patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis patients with acute leukemia. Clin Infect Dis 22:1064, 1996.
46:201, 2008. 95. Rammaert B, Desjardins A, Lortholary O: New insights into hepatosplenic candidosis,
65. Park WB, Kim NH, Kim KH, et al: The effect of therapeutic drug monitoring on safety a manifestation of chronic disseminated candidosis. Mycoses 55:e74, 2012.
and efficacy of voriconazole in invasive fungal infections: A randomized controlled 96. Anttila VJ, Ruutu P, Bondestam S, et al: Hepatosplenic yeast infection in patients with
trial. Clin Infect Dis 55:1080, 2012. acute leukemia: A diagnostic problem. Clin Infect Dis 18:979, 1994.
66. Raad II, Hanna HA, Boktour M, et al: Novel antifungal agents as salvage therapy for 97. Torres-Valdivieso MJ, Lopez J, Melero C, et al: Hepatosplenic candidosis in an immu-
invasive aspergillosis in patients with hematologic malignancies: Posaconazole com- nosuppressed patient responding to fluconazole. Mycoses 37:443, 1994.
pared with high-dose lipid formulations of amphotericin B alone or in combination 98. Arda B, Soyer N, Sipahi OR, et al: Possible hepatosplenic candidiasis treated with
with caspofungin. Leukemia 22:496, 2008. liposomal amphotericin B and caspofungin combination. J Infect 52:387, 2006.
67. Vehreschild JJ, Birtel A, Vehreschild MJ, et al: Mucormycosis treated with posaconazole: 99. Walsh TJ, Whitcomb P, Piscitelli S, et al: Safety, tolerance, and pharmacokinetics of
Review of 96 case reports. Crit Rev MicrobiolMicrobiology 39:310, 2013. amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob
68. Falci DR, Pasqualotto AC: Profile of isavuconazole and its potential in the treatment of Agents Chemother 41:1944, 1997.
severe invasive fungal infections. Infect Drug Resist 6:163, 2013. 100. Legrand F, Lecuit M, Dupont B, et al: Adjuvant corticosteroid therapy for chronic dis-
69. Colombo AL, Ngai AL, Bourque M, et al: Caspofungin use in patients with invasive seminated candidiasis. Clin Infect Dis 46:696, 2008.
candidiasis caused by common non-albicans Candida species: Review of the caspofun- 101. Chen CY, Chen YC, Tang JL, et al: Hepatosplenic fungal infection in patients with
gin database. Antimicrob Agents Chemother 54:1864, 2010. acute leukemia in Taiwan: Incidence, treatment, and prognosis. Ann Hematol 82:93,
70. Mikulska M, Viscoli C: Current role of echinocandins in the management of invasive 2003.
aspergillosis. Curr Infect Dis Rep 13:517, 2011. 102. Mermel LA, Allon M, Bouza E, et al: Clinical practice guidelines for the diagnosis and
71. Enoch DA, Idris SF, Aliyu SH, et al: Micafungin for the treatment of invasive aspergil- management of intravascular catheter-related infection: 2009 Update by the Infectious
losis. J Infect 68:507, 2014. Diseases Society of America. Clin Infect Dis 49:1, 2009.
72. Zhang M, Sun W, Wu T, et al: Efficacy of combination therapy of triazole and echi- 103. Hanna H, Afif C, Alakech B, et al: Central venous catheter-related bacteremia due to
nocandin in treatment of invasive aspergillosis: A systematic review of animal and gram-negative bacilli: Significance of catheter removal in preventing relapse. Infect
human studies. J Thorac Dis 6:99, 2014. Control Hosp Epidemiol 25:646, 2004.
73. Reboli AC, Rotstein C, Pappas PG, et al: Anidulafungin versus fluconazole for invasive 104. Ghanem GA, Boktour M, Warneke C, et al: Catheter-related Staphylococcus aureus bac-
candidiasis. N Engl J Med 356:2472, 2007. teremia in cancer patients: High rate of complications with therapeutic implications.
74. Shankar SM, Nania JJ: Management of Pneumocystis jiroveci pneumonia in children Medicine (Baltimore) 86:54, 2007.
receiving chemotherapy. Paediatr Drugs 9:301, 2007. 105. Raad I, Hanna H, Boktour M, et al: Management of central venous catheters in patients
75. Lemiale V, Debrumetz A, Delannoy A, et al: Adjunctive steroid in HIV-negative with cancer and candidemia. Clin Infect Dis 38:1119, 2004.
patients with severe Pneumocystis pneumonia. Respir Res 14:87, 2013. 106. Jaeger K, Zenz S, Juttner B, et al: Reduction of catheter-related infections in neutropenic
76. Almyroudis NG, Segal BH: Prevention and treatment of invasive fungal diseases in patients: A prospective controlled randomized trial using a chlorhexidine and silver
neutropenic patients. Curr Opin Infect Dis 22:385, 2009. sulfadiazine-impregnated central venous catheter. Ann Hematol 84:258, 2005.
77. Cordonnier C, Pautas C, Maury S, et al: Empirical versus preemptive antifungal therapy 107. Flowers CR, Seidenfeld J, Bow EJ, et al: Antimicrobial prophylaxis and outpatient man-
for high-risk, febrile, neutropenic patients: A randomized, controlled trial. Clin Infect agement of fever and neutropenia in adults treated for malignancy: American Society
Dis 48:1042, 2009. of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794, 2013.
78. Pagano L, Caira M, Nosari A, et al: The use and efficacy of empirical versus pre-emptive 108. Freifeld A, Sepkowitz K: The conundrum of fluoroquinolone prophylaxis. Nat Clin
therapy in the management of fungal infections: The HEMA e-Chart Project. Haemato- Pract Oncol 3:524, 2006.
logica 96:1366, 2011. 109. Moores KG: Safe and effective outpatient treatment of adults with chemotherapy-in-
79. Tan BH, Low JG, Chlebicka NL, et al: Galactomannan-guided preemptive vs. empirical duced neutropenic fever. Am J Health Syst Pharm 64:717, 2007.
antifungals in the persistently febrile neutropenic patient: A prospective randomized 110. Gafter-Gvili A, Fraser A, Paul M, et al: Antibiotic prophylaxis for bacterial infections
study. Int J Infect Dis 15:e350, 2011. in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev
80. Senn L, Robinson JO, Schmidt S, et al: 1,3-Beta-D-glucan antigenemia for early diagno- 1:CD004386, 2012.
sis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect 111. Cullen M, Steven N, Billingham L, et al: Antibacterial prophylaxis after chemotherapy
Dis 46:878, 2008. for solid tumors and lymphomas. N Engl J Med 353:988, 2005.
81. Pfeiffer CD, Fine JP, Safdar N: Diagnosis of invasive aspergillosis using a galactoman- 112. Macesic N, Morrissey CO, Cheng AC, et al: Changing microbial epidemiology in
nan assay: A meta-analysis. Clin Infect Dis 42:1417, 2006. hematopoietic stem cell transplant recipients: Increasing resistance over a 9-year
82. McMullan R, Metwally L, Coyle PV, et al: A prospective clinical trial of a real-time period. Transpl Infect Dis 16:887, 2014.
polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, 113. Bow EJ: Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
critically ill adults. Clin Infect Dis 46:890, 2008. Curr Opin Infect Dis 24:545, 2011.
83. Hachem R, Hanna H, Kontoyiannis D, et al: The changing epidemiology of invasive 114. Leibovici L, Paul M, Cullen M, et al: Antibiotic prophylaxis in neutropenic patients:
candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia New evidence, practical decisions. Cancer 107:1743, 2006.
in hematologic malignancy. Cancer 112:2493, 2008. 115. Alonso CD, Treadway SB, Hanna DB, et al: Epidemiology and outcomes of Clostrid-
84. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al: Epidemiological cutoffs and ium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis
cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 54:1053, 2012.
52:2468, 2008. 116. Cartman ST, Heap JT, Kuehne SA, et al: The emergence of “hypervirulence” in Clostrid-
85. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, Walsh T: Interventions for the pre- ium difficile. Int J Med Microbiol 300:387, 2010.
vention and treatment of herpes simplex virus in patients being treated for cancer. 117. Trecarichi EM, Tumbarello M: Antimicrobial-resistant Gram-negative bacteria in
Cochrane Database Syst Rev (1):CD006706, 2009. febrile neutropenic patients with cancer: Current epidemiology and clinical impact.
86. Biron KK: Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154, 2006. Curr Opin Infect Dis 27:200, 2014.
87. Almyroudis NG, Jakubowski A, Jaffe D, et al: Predictors for persistent cytomegalovirus 118. Prabhu RM, Piper KE, Litzow MR, et al: Emergence of quinolone resistance among
reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation. viridans group streptococci isolated from the oropharynx of neutropenic peripheral
Transpl Infect Dis 9:286, 2007. blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur
88. Chemaly RF, Shah DP, Boeckh MJ: Management of respiratory viral infections in J Clin Microbiol Infect Dis 24:832, 2005.
hematopoietic cell transplant recipients and patients with hematologic malignancies. 119. Baden LR: Prophylactic antimicrobial agents and the importance of fitness. N Engl J
Clin Infect Dis 59 (Suppl 5):S344, 2014. Med 353:1052, 2005.
89. Chemaly RF, Torres HA, Aguilera EA, et al: Neuraminidase inhibitors improve out- 120. Verlinden A, Jansens H, Goossens H, et al: Clinical and microbiological impact of
come of patients with leukemia and influenza: An observational study. Clin Infect Dis discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound
44:964, 2007. neutropenia. Eur J Haematol 93:302, 2014.
90. Al-Anazi KA, Al-Jasser AM, Evans DA: Infections caused by mycobacterium tubercu- 121. Kern WV, Klose K, Jellen-Ritter AS, et al: Fluoroquinolone resistance of Escherichia
losis in patients with hematological disorders and in recipients of hematopoietic stem coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophy-
cell transplant, a twelve year retrospective study. Ann Clin Microbiol Antimicrob 6:16, lactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol
2007. Infect Dis 24:111, 2005.
91. Wright A, Zignol M, Van Deun A, et al: Epidemiology of antituberculosis drug resis- 122. Reuter S, Kern WV, Sigge A, et al: Impact of fluoroquinolone prophylaxis on reduced
tance 2002-07: An updated analysis of the Global Project on Anti-Tuberculosis Drug infection-related mortality among patients with neutropenia and hematologic malig-
Resistance Surveillance. Lancet 373:1861, 2009. nancies. Clin Infect Dis 40:1087, 2005.

Kaushansky_chapter 24_p0383-0392.indd 391 9/17/15 5:58 PM